ESMOGI24 Key Insights Shared By Megan Barnet
ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024, as well as online, through a dedicated virtual platform. The congress will be the place to present impactful new data in GI oncology.
Megan Barnet, Medical Oncologist at The Kinghorn Cancer Centre, shared a few highlights from the conference.
TOPAZ-1 update at mFU 41 months – OS HR strengthened 0.8 —> 0.74, if have a CR/PR 1/3 alive at 3 years vs 16% chemo. 17% ‘long term’ survivors, across all subgroups: iCCA/eCCA/GBC/ROW/PDL1
BRAFm and mCRC trials with Dominik Paul Modest
Summary ongoing BRAFm and mCRC trials with Dominik Paul Modest
- 1L BREAKWATER MSS Phase 3 enco/cetux +/CT vs CT-bev 1L SEAMARK MSI Ph2 enco/cetux/pembro vs pembro
- 2L SWOG2107 MSS Phase 2 enco/cetux v enco/cetux/nivo
- 3L BRICKET Phase2 rechallenge enco/cetux if no alternate ctDNA
PDAC has more negative trials than any other tumour stream… Trying to find Thomas Seufferlein’s summary slide motivating rather than deflating. Nal-iri combos underwhelming and not compared to FOLFIRI/mFFX.
Why radio-oncologists dislike PROSPECT
A reminder from Professor Karin Haustermans of why radio-oncologists dislike PROSPECT (…aside from inclusion of patients who didn’t need NA treatment).
Thought provoking talk from Irit Ben-Aharon on QoL issues in EOCRC, especially paucity of data on fertility with RT plus oxali (can’t extrapolate GnRHa from CTX – can worsen problem), cardiovascular toxicity (CVD 54% CRC survivors v 17% Gen pop), psychosocial, body image, sexual functions.
KN585 OS (noting EFS/trial stat. negative despite 20m improvement)
- OS benefit 6% at 5 years.
- FLOT (v CF) backbone did better (cis poor PD1 partner), but only 20% cohort
- Clear benefit CPS >10/MSI-H.
- Appealing option; may solidify with MATTERHORN survival (100% FLOT)
Interesting summary from Chiara Cremolini
Unsurprising QoL data for TRANSMET, late deviation in favour LT+C vs C. Interesting summary from Chiara Cremolini on pattern of relapse liver TP (lung dominant) vs resection (liver dominant).
Meta-analysis on gut microbiome
Laurence Zitvogel tour de force microbiome. Meta-analysis:
- AB use -60 to +42d C1 PD1;
- surge pathogenic bacteria
- Post AB down-regulation of gut checkpoint MadCAM
- exodus immunosuppressive cells increases Th17 from gut to cancer
- PD1 at this point amplifies exodus/doc/hard place
For more coverage on ESMOGI24, visit the OncoDaily website.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023